24-Apr-2024	Ceasing to be a substantial holder

8-Apr-2024	Application for quotation of securities - CYC

26-Mar-2024	Appendix 4G

25-Mar-2024	Voluntary Escrow Shares to be Released

25-Mar-2024	Date of Annual General Meeting

19-Mar-2024	First USA Patients Imaged with Technegas

1-Mar-2024	S&P DJI Announces March 2024 Quarterly Rebalance

19-Feb-2024	CYC Board Changes

19-Feb-2024	Initial Director's Interest Notice

12-Feb-2024	Cyclopharm Appoints Jason Smith as CFO

6-Feb-2024	Cyclopharm to Present at Euroz Hartleys Healthcare Forum

5-Feb-2024	Cyclopharm Trading and USA Launch Update

29-Jan-2024	CYC and Yale Translational Research Partner on Technegas

5-Dec-2023	Cyclopharm Signs First USA Contract for Technegas

1-Dec-2023	Change of Director's Interest Notice

1-Dec-2023	Application for quotation of securities - CYC

15-Nov-2023	Technegas USA Commercialisation Update

2-Nov-2023	Change of Director's Interest Notice

1-Nov-2023	Change of Director's Interest Notice

5-Oct-2023	CYC USFDA Approval Webinar Presentation

3-Oct-2023	FDA Technegas Approval Webinar

3-Oct-2023	SNMMI Announcement Regarding USFDA Approval of Technegas

2-Oct-2023	Cyclopharm Receives USFDA Approval for Technegas

26-Sep-2023	Cyclopharm Investor Update

26-Sep-2023	Investor Presentation Correction

26-Sep-2023	Investor Presentation Correction

12-Sep-2023	Application for quotation of securities - CYC

25-Aug-2023	Litigation Update and Receipt of Settlement Payment

22-Aug-2023	Dividend/Distribution - CYC

9-Aug-2023	USFDA Approval Process Update

17-Jul-2023	Cyclopharm 2023 Half Year Accounts Update - Record Revenues

16-May-2023	Notification of buy-back - CYC

16-May-2023	Results of Meeting

16-May-2023	Managing Director's Address to Shareholders

16-May-2023	CYC 2023 AGM Presentation

16-May-2023	Chairman's Address to Shareholders

9-May-2023	Cyclopharm Confirms USFDA Scheduled Inspection Date

24-Apr-2023	USFDA Confirms Technegas Six Month Review Period

20-Apr-2023	Cyclopharm Acquires DuPharma ApS

18-Apr-2023	Application for quotation of securities - CYC

17-Apr-2023	Proposed issue of securities - CYC

13-Apr-2023	Notice of Annual General Meeting/Proxy Form

5-Apr-2023	Cyclopharm USFDA Approval Progress Update

31-Mar-2023	Appendix 4G

30-Mar-2023	Technegas Enters Final Six Month USFDA Review Cycle

24-Mar-2023	Application for quotation of securities - CYC

15-Mar-2023	Date of Annual General Meeting

20-Feb-2023	Dividend/Distribution - CYC

5-Dec-2022	Change of Director's Interest Notice - KBarrow

30-Nov-2022	Change of Director's Interest Notice - DAngus

9-Nov-2022	Bell Potter Healthcare Conference Directors Profile

9-Nov-2022	Bell Potter Healthcare Conference

5-Oct-2022	Notification of cessation of securities - CYC

27-Sep-2022	CYC Board Changes

27-Sep-2022	Initial Director's Interest Notice

1-Sep-2022	Initial Director's Interest Notice

1-Sep-2022	CYC Board Changes

17-Aug-2022	Dividend/Distribution - CYC

7-Jul-2022	Technegas Used In Multicenter COVID Study

4-Jul-2022	1H 2022 Business Update - Record Revenues

14-Jun-2022	Change of Director's Interest Notice

24-May-2022	CYC Investor Presentation 24 May 2022

24-May-2022	Technegas used in Diagnosing Long COVID

23-May-2022	Change of Director's Interest Notice

17-May-2022	Results of Meeting

17-May-2022	Managing Director's Address to Shareholders

17-May-2022	CYC 2022 AGM Presentation

17-May-2022	Chairman's Address to Shareholders

14-Apr-2022	Notice of Annual General Meeting/Proxy Form

31-Mar-2022	Appendix 4G

16-Mar-2022	Date of Annual General Meeting

9-Mar-2022	Change of Director's Interest Notice

4-Mar-2022	S&P DJI Announces March 2022 Quarterly Rebalance

23-Feb-2022	Dividend/Distribution - CYC

3-Feb-2022	Cyclopharm USFDA Update

1-Dec-2021	Final Director's Interest Notice

1-Dec-2021	Board Update

9-Nov-2021	Bell Potter HealthCare Conference

23-Aug-2021	Dividend/Distribution - CYC

10-Aug-2021	Initial Director's Interest Notice

10-Aug-2021	CYC Board Changes

28-Jun-2021	Cyclopharm USFDA Update

7-Jun-2021	Ceasing to be a substantial holder from MUFG

4-Jun-2021	Ceasing to be a substantial holder from MS

4-Jun-2021	Becoming a substantial holder from MUFG

4-Jun-2021	Becoming a substantial holder from MS

3-Jun-2021	Ceasing to be a substantial holder from MUFG

2-Jun-2021	Ceasing to be a substantial holder from MS

1-Jun-2021	Becoming a substantial holder from MUFG

31-May-2021	Becoming a substantial holder from MS

26-May-2021	Ceasing to be a substantial holder from MUFG

25-May-2021	Ceasing to be a substantial holder from MS

24-May-2021	Becoming a substantial holder from MUFG

21-May-2021	Becoming a substantial holder from MS

20-May-2021	Ceasing to be a substantial holder from MUFG

20-May-2021	Ceasing to be a substantial holder from MS

19-May-2021	Becoming a substantial holder from MUFG

18-May-2021	Becoming a substantial holder from MS

18-May-2021	Ceasing to be a substantial holder from MUFG

18-May-2021	Ceasing to be a substantial holder from MS

13-May-2021	Becoming a substantial holder from MUFG

13-May-2021	Becoming a substantial holder from MS

11-May-2021	Ceasing to be a substantial holder from MUFG

10-May-2021	Ceasing to be a substantial holder from MS

7-May-2021	Becoming a substantial holder from MUFG

6-May-2021	Ceasing to be a substantial holder from MUFG

5-May-2021	Becoming a substantial holder from MS

4-May-2021	CYC Amended Constitution

4-May-2021	Results of Meeting

4-May-2021	Becoming a substantial holder from MUFG

4-May-2021	Ceasing to be a substantial holder from MUFG

4-May-2021	Managing Director's Address to Shareholders

4-May-2021	CYC 2021 AGM Presentation

4-May-2021	Chairman's Address to Shareholders

3-May-2021	Ceasing to be a substantial holder from MS

30-Apr-2021	Becoming a substantial holder from MS

29-Apr-2021	Ceasing to be a substantial holder from MS

20-Apr-2021	Becoming a substantial holder from MUFG

19-Apr-2021	Becoming a substantial holder from MS

19-Apr-2021	Ceasing to be a substantial holder from MUFG

16-Apr-2021	Ceasing to be a substantial holder from MS

15-Apr-2021	Becoming a substantial holder from MUFG

14-Apr-2021	Becoming a substantial holder from MS

30-Mar-2021	Notice of Annual General Meeting/Proxy Form

29-Mar-2021	Appendix 4G

26-Mar-2021	Change of Share Registry Details

12-Mar-2021	S&P DJI Announces March 2021 Quarterly Rebalance

12-Mar-2021	Confirmation of Technegas USFDA Timetable

8-Mar-2021	Change of Director's Interest Notice - DH

3-Mar-2021	Change of Director's Interest Notice - TM

3-Mar-2021	Date of Annual General Meeting

25-Feb-2021	Dividend/Distribution - CYC

24-Feb-2021	Change of Director's Interest Notice DH

24-Feb-2021	Change of Director's Interest Notice TM

19-Feb-2021	Appendix 2A LTIP

19-Feb-2021	Appendix 2A SPP

17-Feb-2021	Appendix 3B - Amended

17-Feb-2021	Cyclopharm Announces Results of Share Purchase Plan Offer

10-Feb-2021	Change in substantial holding - Chemical Overseas

10-Feb-2021	Change in substantial holding - Barings

8-Feb-2021	Change in substantial holding

4-Feb-2021	Change in substantial holding from CVC

3-Feb-2021	Change of substantial shareholding from AEF

1-Feb-2021	Share Purchase Plan Offer Booklet

1-Feb-2021	Appendix 2A - Placement

1-Feb-2021	Cleansing Notice - Share Purchase Plan

1-Feb-2021	Cleansing Notice - Placement

29-Jan-2021	Change in substantial holding

29-Jan-2021	Change in substantial shareholding from AEF

25-Jan-2021	Proposed issue of Securities - CYC

25-Jan-2021	Cyclopharm Capital Raising Presentation

25-Jan-2021	Cyclopharm Successfully Completes A$30 Million Placement

22-Jan-2021	SNMMI Requests USFDA to Expedite Approval For Technegas

21-Jan-2021	Trading Halt

14-Jan-2021	USFDA Approval Progress for Technegas and Business Update

26-Nov-2020	Bell Potter Healthcare Conference

22-Oct-2020	Change of Director's Interest Notice TM

1-Oct-2020	Change of Director's Interest Notice

29-Sep-2020	Change of Director's Interest Notice

23-Sep-2020	Cyclopharm Investor Presentation

15-Sep-2020	Technegas USA Trial Successfully Meets Primary Endpoint

9-Sep-2020	CYC Partners With McMasters University In COVID-19 Research

25-Aug-2020	Dividend/Distribution - CYC

27-Jul-2020	Change of Director's Interest Notice

27-Jul-2020	Appendix 2A

9-Jul-2020	Results of Meeting

9-Jul-2020	Managing Director's Address to Shareholders

9-Jul-2020	CYC 2020 AGM Presentation

9-Jul-2020	Chairman's Address to Shareholders

5-Jun-2020	Notice of Annual General Meeting/Proxy Form

29-May-2020	Technegas Approved in Russia - Clarification

27-May-2020	USFDA Approval to File Received for Technegas

26-May-2020	Technegas Approved in Russia

21-May-2020	Final share buy-back notice - Appendix 3F

6-May-2020	Form 484 cancellation of Long Term Incentive Plan shares

5-May-2020	Appendix 2A

14-Apr-2020	USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver

31-Mar-2020	CYC Appendix 4G

30-Mar-2020	Cyclopharm Lodges NDA for Technegas with the USFDA

24-Mar-2020	Cyclopharm Company Update

17-Mar-2020	Change of Director's Interest Notice

17-Mar-2020	Change of Director's Interest Notice

13-Mar-2020	Change of Director's Interest Notice

3-Mar-2020	Cyclopharm Investor Presentation

2-Mar-2020	Change of Director's Interest Notice

26-Feb-2020	Dividend/Distribution - CYC

15-Jan-2020	Change in substantial holding

15-Jan-2020	Change in substantial holding

13-Jan-2020	Change in substantial holding

3-Jan-2020	Becoming a substantial holder

2-Jan-2020	Change in substantial holding from CVC

2-Jan-2020	Change in substantial holding from AEF

31-Dec-2019	Becoming a substantial holder

31-Dec-2019	Appendix 3B

30-Dec-2019	Change of Director's Interest Notice

20-Dec-2019	CYC Institutional Placement - Premium To Share Price

20-Dec-2019	AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS

19-Dec-2019	Trading Halt

19-Dec-2019	Pause in Trading

19-Dec-2019	Appendix 3B

12-Dec-2019	Change of Director's Interest Notice JM

12-Dec-2019	Appendix 3B

27-Nov-2019	Final Director's Interest Notice

27-Nov-2019	Board Update

21-Oct-2019	Cyclopharm Investor Presentation - TechKnow Invest Roadshow

30-Sep-2019	Cyclopharm Strengthens Leadership Team

22-Aug-2019	Dividend/Distribution - CYC

26-Jul-2019	Cyclopharm Investor Presentation - Bioshares 2019

27-Jun-2019	Change of Director's Interest Notice - TM

13-Jun-2019	Change of Director's Interest Notice - TM

31-May-2019	Appendix 3B LTIP

27-May-2019	Change of Director's Interest Notice

27-May-2019	Appendix 3B

21-May-2019	Announcement of buy-back - Appendix 3C

21-May-2019	Results of Meeting

21-May-2019	Managing Director's Address to Shareholders

21-May-2019	CYC 2019 AGM Presentation

21-May-2019	Chairman's Address to Shareholders

20-May-2019	Final share buy-back notice - Appendix 3F

18-Apr-2019	Notice of General Meeting/Proxy Form

4-Apr-2019	Cyclopharm Investor Presentation

3-Apr-2019	Change of Director's Interest Notice

29-Mar-2019	CYC Appendix 4G

29-Mar-2019	Annual Report to shareholders

27-Feb-2019	Dividend/Distribution - CYC

29-Oct-2018	CYC - FNN Interview

12-Oct-2018	Positive USFDA Meeting - Technegas sales expected in 2019

9-Oct-2018	CYC Form 484 Cancellation of Long Term Incentive Plan shares

17-Sep-2018	Change of Director's Interest Notice VG

17-Sep-2018	Response to ASX Appendix 3Y Query

12-Sep-2018	Change of Director's Interest Notice VG

4-Sep-2018	Cyclopharm FNN Investor Event

23-Aug-2018	Dividend/Distribution - CYC

13-Aug-2018	Change in substantial holding from CVC

10-Aug-2018	Change in substantial holding from AEF

2-Jul-2018	Appendix 3B LTIP

28-Jun-2018	Change of Director's Interest Notice

27-Jun-2018	Change of Director's Interest Notice - Amended

26-Jun-2018	Change of Director's Interest Notice

14-Jun-2018	Change in substantial holding from CVC

13-Jun-2018	Change in substantial holding from AEF

29-May-2018	Announcement of buy-back - Appendix 3C

29-May-2018	Results of Meeting

29-May-2018	CYC 2018 AGM Presentation

29-May-2018	Managing Director's Address to Shareholders

29-May-2018	Chairman's Address to Shareholders

28-May-2018	Final share buy-back notice - Appendix 3F

17-May-2018	Better Defining Airways Disease with Technegas

7-May-2018	Cyclopharm Acquires Scandinavian Distribution Business

27-Apr-2018	Notice of Annual General Meeting/Proxy Form

29-Mar-2018	40 Patient Milestone Achieved For Technegas USFDA Trial

26-Mar-2018	CYC Appendix 4G

15-Mar-2018	2017 Results Presentation

1-Mar-2018	Change of Director's Interest Notice - David Heaney

26-Feb-2018	Dividend/Distribution - CYC

21-Dec-2017	FNN Interview and Presentation

12-Dec-2017	Cyclopharm FNN Investor Event

20-Nov-2017	Change of Director's Interest Notice - D Heaney